{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:18:52Z","timestamp":1787026732994,"version":"build-2736575974"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Diabetic kidney disease (DKD) is a complication of diabetes that can lead to kidney failure. Over the years, several drugs have been developed to combat this disease. In the early 90s, angiotensin blockade (ACEi and ARBs) was introduced, which revolutionized the treatment of DKD. In recent years, newer drugs such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, endothelin antagonists, and mineralocorticoid receptor antagonists (MRA) have shown great promise in reducing albuminuria and protecting the kidneys. These drugs are being used in combination with lifestyle modifications, patient education, and risk factor modification to effectively manage DKD. In this review, we will explore the latest pharmacological options, their efficacy, and their potential to revolutionize the management of this debilitating disease.<\/jats:p>","DOI":"10.3389\/fmed.2023.1264497","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T13:35:10Z","timestamp":1701437710000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment and practical considerations of diabetic kidney disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Yara","family":"Bilen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allaa","family":"Almoushref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenda","family":"Alkwatli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mehdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanny","family":"Sawaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"ref1","year":"2023"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41581-018-0001-y","article-title":"CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease","volume":"14","author":"Anders","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4093\/dmj.2020.0217","article-title":"Treatment of diabetic kidney disease: current and future","volume":"45","author":"Yamazaki","year":"2021","journal-title":"Diabetes Metab J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/jcm11020378","article-title":"Therapeutic advances in diabetic nephropathy","volume":"11","author":"Sawaf","year":"2022","journal-title":"J Clin Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jvim.15454","article-title":"The renin-angiotensin-aldosterone system and its suppression","volume":"33","author":"Ames","year":"2019","journal-title":"J Vet Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000184318","article-title":"Antiproteinuric effect of captopril in primary glomerular disease","volume":"46","author":"Lagrue","year":"1987","journal-title":"Nephron"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2337\/dc06-1998","article-title":"Prevention of transition from incipient to overt nephropathy with Telmisartan in patients with type 2 diabetes","volume":"30","author":"Makino","year":"2007","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMsa1213829","article-title":"Achievement of goals in U.S. diabetes care, 1999\u20132010","volume":"368","author":"Ali","year":"2013","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor\u2013associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2109794","article-title":"24-hour urinary sodium and potassium excretion and cardiovascular risk","volume":"386","author":"Ma","year":"2022","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1097\/HJH.0000000000001456","article-title":"In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review","volume":"35","author":"Fitton","year":"2017","journal-title":"J Hypertens"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2710.2008.00938.x","article-title":"Use of ACE inhibitors and ARBs in hypertensive women of childbearing age","volume":"33","author":"Martin","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin\u2013angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/ndt\/15.4.487","article-title":"The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics","volume":"15","author":"Rodby","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Or both in patients at high risk for vascular events","volume":"358","author":"Telmisartan","year":"2008","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"ref25","year":"2008"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na+\/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am J Physiol Renal Fluid Electrol Physiol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors for type 2 diabetes","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by Empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review","volume":"72","author":"Zelniker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1111\/dom.13823","article-title":"Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes","volume":"21","author":"Mulder","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.pcad.2019.07.003","article-title":"Diabetes, heart failure, and renal dysfunction: the vicious circles","volume":"62","author":"Braunwald","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2337\/dc23-Srev","article-title":"Summary of revisions: standards of Care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"ref40","first-page":"117","article-title":"Empagliflozin in patients with chronic kidney disease","volume-title":"N Engl J Med","author":"Herrington","year":"2023"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3389\/fphar.2019.01066","article-title":"Appraisal of non-cardiovascular safety for sodium\u2013glucose co-transporter 2 inhibitors: a systematic review and Meta-analysis of placebo-controlled randomized clinical trials","volume":"10","author":"Shi","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/db19-1224-P","article-title":"1224-P: improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice","volume":"68","author":"WILLIAMS","year":"2019","journal-title":"Diabetes"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2213-8587(20)30311-9","article-title":"SGLT2 inhibitors and renal complications in type 1 diabetes","volume":"8","author":"Petrie","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","article-title":"Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials","volume":"8","author":"Groop","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13300-015-0117-z","article-title":"Efficacy and safety of Canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial","volume":"6","author":"Fulcher","year":"2015","journal-title":"Diabet Therap Res Treat Educ Diabet Disord"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1111\/dom.14159","article-title":"Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51\u2009713 individuals","volume":"22","author":"Huang","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","article-title":"Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia","volume":"41","author":"Szalat","year":"2018","journal-title":"Drug Saf"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","article-title":"An overview of GLP-1 agonists and recent cardiovascular outcomes trials","volume":"96","author":"Sheahan","year":"2020","journal-title":"Postgrad Med J"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","article-title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect","volume":"20","author":"Fisman","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"ref53","year":"2023"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0083-6729(08)00615-8","article-title":"Chapter 15 glucose-dependent Insulinotropic polypeptide (gastric inhibitory polypeptide; GIP)","volume-title":"Vitamins & Hormones, Insulin and IGFs","author":"McIntosh","year":"2009"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1210\/clinem\/dgad076","article-title":"GLP-1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: a systematic review and Meta-analysis of randomized controlled trials","volume":"108","author":"Banerjee","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1111\/dom.14175","article-title":"Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: a post hoc analysis of the EXSCEL trial","volume":"22","author":"van der Aart-van der Beek","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly Exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.mce.2011.05.005","article-title":"Central regulation of blood pressure by the mineralocorticoid receptor","volume":"350","author":"Gomez-Sanchez","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"e018827","DOI":"10.1161\/JAHA.120.018827","article-title":"Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension","volume":"9","author":"Tsujimoto","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"425","DOI":"10.34067\/KID.0006782020","article-title":"Patiromer and spironolactone in resistant hypertension and advanced CKD: analysis of the randomized AMBER trial","volume":"2","author":"Agarwal","year":"2021","journal-title":"Kidney"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J Intern Med"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Hypertens"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and Cardiorenal outcomes with Finerenone in chronic kidney disease in type 2 diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"CD007004","DOI":"10.1002\/14651858.CD007004.pub4","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"2020","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"754239","DOI":"10.3389\/fphar.2021.754239","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"12","author":"Kawanami","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","article-title":"Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis","volume":"37","author":"Hou","year":"2015","journal-title":"Clin Ther"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on albuminuria in patients with diabetic nephropathy","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2362.2009.02121.x","article-title":"Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence","volume":"39","author":"Neuhofer","year":"2009","journal-title":"Eur J Clin Investig"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/j.1399-6576.2008.01768.x","article-title":"The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shock","volume":"52","author":"FENHAMMAR","year":"2008","journal-title":"Acta Anaesthesiol Scand"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist Atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2215\/CJN.07040713","article-title":"Predictors of congestive heart failure after treatment with an endothelin receptor antagonist","volume":"9","author":"Hoekman","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","article-title":"New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction","volume":"99","author":"Heerspink","year":"2021","journal-title":"Kidney Int"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2215\/CJN.00560122","article-title":"Endothelin receptor antagonists for kidney protection: lessons from the SONAR trial","volume":"17","author":"Heerspink","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1183\/16000617.0079-2016","article-title":"Pregnancy in pulmonary arterial hypertension","volume":"25","author":"Olsson","year":"2016","journal-title":"Eur Respir Rev"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1183\/09031936.00094409","article-title":"Liver toxicity: the Achilles\u2019 heel of endothelin receptor antagonist therapy?","volume":"34","author":"Hoeper","year":"2009","journal-title":"Eur Respir J"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"e003896","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the Meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000506634","article-title":"Diabetic kidney disease: challenges, advances, and opportunities","volume":"6","author":"Chen","year":"2020","journal-title":"Kidney Dis"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/labinvest.2017.2","article-title":"APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db\/db mice from renal injury","volume":"97","author":"Cha","year":"2017","journal-title":"Lab Investig"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"F1276","DOI":"10.1152\/ajprenal.00396.2014","article-title":"Targeting NADPH oxidase with a novel dual Nox1\/Nox4 inhibitor attenuates renal pathology in type 1 diabetes","volume":"308","author":"Gorin","year":"2015","journal-title":"Am J Physiol Ren Physiol"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.ajpath.2017.07.020","article-title":"Systemic monocyte chemotactic Protein-1 inhibition modifies renal macrophages and restores glomerular endothelial Glycocalyx and barrier function in diabetic nephropathy","volume":"187","author":"Boels","year":"2017","journal-title":"Am J Pathol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s10157-020-01917-5","article-title":"Bardoxolone methyl: drug development for diabetic kidney disease","volume":"24","author":"Kanda","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"3","DOI":"10.12861\/jrip.2012.02","article-title":"Silymarin and diabetic nephropathy","volume":"1","author":"Rafieian-Kopaie","year":"2012","journal-title":"J Ren Inj Prev"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of Linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"ii3-ii9","DOI":"10.1093\/ndt\/gfab045","article-title":"Precision medicine approaches for diabetic kidney disease: opportunities and challenges","volume":"36","author":"Tye","year":"2021","journal-title":"Nephrol Dial Transplant"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1264497\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T13:35:31Z","timestamp":1701437731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1264497\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":100,"alternative-id":["10.3389\/fmed.2023.1264497"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1264497","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"article-number":"1264497"}}